go sg websit
recent launch product drive medium-term growth
upsid tp
nc chang
on-going portfolio rejuven off-set patent expiri
medium term earn growth broadli line pharma sector
justifi current valuat hold rate reiter
mix newsflow portfolio
lilli perform line us pharma sector
past six month albeit one year compani face
challeng diabet new competit price pressur seen delay
pipelin product olumi setback alzheim research bace class trial
recent launch dynam product inflamm cancer environ
portfolio rejuven on-going lilli process rejuven portfolio
almost sale set lose exclus ciali cardio alimta
cancer although end latter howev
off-set recent launch product taltz olumi immune-inflamm
blockbust potenti combin look like account
group sale verzenio breast cancer sale three drug set
account almost half growth estim potenti growth driver
includ diabet trulic weekli despit new competit novo
ozemp jardianc given cardiovascular benefit profil oral market
overal growth profil remain broadli line peer lower forecast
one year ago lilli setback research alzheim mainli seen
delay highli competit market rheumatoid arthriti
hold reiter nudg estim reflect stronger competit
recent launch product trim target price accordingli
despit on-going portfolio rejuven end patent protect pharma
product continu weigh growth lilli earn growth profil broadli line
sector stock trade premium peer
price-to-earnings estim line consensu medium term lower long
term give lilli benefit doubt earli phase pipelin
bull/bear approach show balanc profil ebit newsflow
outcom trulic trial seen help compet novo ozemp although
benefit market expans
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
lilli perform broadli line pharma sector past six month lilli
almost pure pharma compani strong histori innov three area diabet
first insulin central nervou system although product end
life cycl prozac depress zyprexa schizophrenia cancer
focus portfolio compani abl find outsid partner strengthen
franchis boehring ingelheim deal diabet azn alzheim lilli also
second pillar anim health oper elanco strengthen
acquisit novarti anim health busi howev follow difficulti re-
energis divis lilli current explor option dispos spin-off
lilli sale breakdown categori
growth driver well track
shown chart main headwind deriv genericis product
strattera adhd alimta cancer although us protect valid
follow recent posit court decis ciali cardiolog tail portfolio altogeth
product account almost total group sale pipelin contribut
compani off-set gradual eros
detail pie chart chart main growth driver come
launch product compris product
olumiant/baricitinib rheumatoid arthriti avail europ delay us although
approv expect year taltz psoriasi spondyloarthr cancer
vereznio/abemaciclib howev diabet remain strong contributor jardianc
trulic
estim broadli line short term start diverg
conserv assumpt potenti new product oper profit
margin expans shown
adjust estim slightli reflect competit recent launch
product market nudg target price tp accordingli also take
account recent sector multipl collaps shown tabl tp
averag sum-of-the-part dcf tp lilli share would trade
premium pharma sector
valuat tp adjust vs
part
sop base follow assumpt
pharma valu premium vs previous larg pharma peer
group given lilli innov profil medium-term growth driven recent launch
product also slowdown due gener beyond
anim health valu divis premium larg pharma peer given
current challeng busi face
expect group margin improv thank anim health contribut synergi
novarti transact favour product mix new product
off-set patent expiri short term
sop valuat come bit dcf also captur long-term valu
compani driven pipelin recent launch product expect
account almost sale
multipl
multipl
chart lilli sale ep growth clearli illustr gener impact beyond
bull bear scenario show balanc risk reward profil
late-stag product potenti reflect core scenario apart alzheim
remain prematur even add best-cas scenario given multipl setback
across area lilli present bace inhibitor merck co
bull bear scenario impact sale
bull bear scenario impact ebita
bull bear scenario impact sale categori
bull bear scenario impact ebita categori
lilli forward price-to-earnings base consensu us pharma sector
slightli ten-year averag premium even record high
relev newsflow come view product alreadi approv
diabet outcom trulic lesser extent trajenta dpp-iv
trial us final approv olumi delay would reassur although alreadi
approv europ
osteoarthr hip knee
bull/bear scenario potenti impact ebit
pressur biosimilar san
slightli lower penetr
price war new biosimilar
slightli better penetr line
growth
strong penetr due better
limit adopt
approv
approv
product sold
equival
total liabil equiti
chang work capit
flow oper activ
flow invest activ
net chang debt
purchas common stock
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
food
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
tp deriv sotp averag valuat obtain appli averag ev/ebita multipl pharma peer
group premium pharma divis line anim health ii dcf lt growth lt ebita margin
downsid stronger competit recent launch product cancer immune-inflamm would low- mid-singl
digit impact ebit two indic trulic trial result disappoint low mid singl digit neg
impact ebit
upsid better penetr talz psoriasi high-single-digit upsid ebit faster recoveri anim health divis low singl
digit posit impact ebit
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ sa bond issu senior
sg act co-manag novarti financ bond
